Active compounds form the basis of many common cosmetics, pharmaceutical products, and nutraceuticals.
Tagra Biotechnologies has developed innovative technologies, including microencapsulation and novel chemical syntheses, for protecting specialized active ingredients and compounds used in the personal care and pharmaceutical industries. Using the company’s technologies, these industries can meet the challenges of finding with solutions to problems related to stability, activity and safety of active ingredients and complexes.

 

TECHNOLOGY
The personal care and pharmaceutical industries are continuously faced with the problem that most active ingredients, which provide the required biological activity on the one hand, are, on the other, inherently unstable, especially in finished formulations.

Tagra’s innovative technologies and products stabilize these active ingredients assuring their effective delivery and targeted release.

Tagra’s versatile technological capabilities have led to the development of off-the-shelf active ingredients and complexes and customized products. Tagra’s commercial range includes:

Ron Folman, CEO

Emma Kvitnitsky, director, technology and product development

Eran Meiraz, business development manager